Discovery & Clinical Translation of a Small-Molecule Inhibitor of α-Synuclein Toxicity

Time: 3:50 pm
day: Day One


• Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCD) potently protect cells from α-synuclein toxicity
• Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies
• Focusing on the preclinical discovery and recent Phase Ia human clinical data from our lead SCD inhibitor, YTX-7739